Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 19, Issue 1, 2022

Background: Prostate Cancer (PCa) is a non-cutaneous malignancy in men, and Decipher being a genomic test, has gained increasing attention in estimating the risk of developing a recurrence or metastatic PCa disease in patients. Therefore, this study is focused on evaluating the association of Decipher score risk with recurrence of prostate cancer patients based on their medical, genetic predictors, and demographics (e.g., r Read More

Background: To reduce the side effects of conventional chemotherapy drugs, new herbal remedies, such as alantolactone, can be used. Objective: We evaluated the association between stemness and EMT (Epithelial- Mesenchymal Transition) process in triple-negative breast cancer cells treated with alantolactone that targets STAT3. Methods: The MDA-MB-231 cell line was used as one of the triple-negative breast cancer cell lines Read More

Background: After completing the human genome, the project has created opportunities to improve the diagnosis, prevention, and treatment of disease. However, the limitations in Health Professionals (HPs), genetic knowledge, technological resources, and a lack of scientific research prevent global genetic screening from being addressed. Objectives: The objective is to evaluate HPs’ knowledge, attitude, and future out Read More

Background: The heterogeneity of some diseases, such as cancer, makes the decisions on therapeutic strategy very challenging. In this context, pathway analysis can support the identification of the best treatment and indeed prevent the issues arising from the trial and error process, in terms of best overall efficacy and lowest toxicity, ultimately saving time and resources. In a pathway, each gene is represented by a nod Read More

Aim: This study aimed to discover the most effective anti-cancer medicine for cancer patients infected with SARS-CoV-2. Background: The correlation between TP53 and SARS-CoV-2 was examined using biomolecular networking analysis. Objective: Cancer patients with TP53 gene mutations are more likely to be infected with the SARS-CoV-2 virus since it is the most frequently mutated tumor suppressor gene in hu Read More